Nothing Special   »   [go: up one dir, main page]

FR2963790B1 - Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires - Google Patents

Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Info

Publication number
FR2963790B1
FR2963790B1 FR1056560A FR1056560A FR2963790B1 FR 2963790 B1 FR2963790 B1 FR 2963790B1 FR 1056560 A FR1056560 A FR 1056560A FR 1056560 A FR1056560 A FR 1056560A FR 2963790 B1 FR2963790 B1 FR 2963790B1
Authority
FR
France
Prior art keywords
docosahexaeneoate
panthenyl
prevention
treatment
cardiovascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1056560A
Other languages
English (en)
Other versions
FR2963790A1 (fr
Inventor
Adam Frederique Lantoine
Robert Letienne
Passelaigue Elisabeth Dupont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR1056560A priority Critical patent/FR2963790B1/fr
Priority to TW100127261A priority patent/TWI555528B/zh
Priority to ARP110102874A priority patent/AR082594A1/es
Priority to BR112013003149A priority patent/BR112013003149A2/pt
Priority to CN201180036873.2A priority patent/CN103025707B/zh
Priority to AU2011288410A priority patent/AU2011288410B2/en
Priority to DK11743536.2T priority patent/DK2603486T3/en
Priority to ES11743536.2T priority patent/ES2531437T3/es
Priority to US13/816,048 priority patent/US20130137768A1/en
Priority to RS20150175A priority patent/RS53896B1/en
Priority to HUE11743536A priority patent/HUE024560T2/hu
Priority to RU2013110131/04A priority patent/RU2593203C2/ru
Priority to KR1020137004509A priority patent/KR20140031830A/ko
Priority to JP2013523623A priority patent/JP5960695B2/ja
Priority to CA2806154A priority patent/CA2806154A1/fr
Priority to PT117435362T priority patent/PT2603486E/pt
Priority to PCT/EP2011/063854 priority patent/WO2012020094A1/fr
Priority to NZ607836A priority patent/NZ607836A/en
Priority to MYPI2013000417A priority patent/MY166065A/en
Priority to EP11743536.2A priority patent/EP2603486B1/fr
Priority to PL11743536T priority patent/PL2603486T3/pl
Priority to MA35677A priority patent/MA34480B1/fr
Priority to MX2013001506A priority patent/MX2013001506A/es
Priority to SI201130418T priority patent/SI2603486T1/sl
Priority to UAA201303028A priority patent/UA109551C2/uk
Publication of FR2963790A1 publication Critical patent/FR2963790A1/fr
Application granted granted Critical
Publication of FR2963790B1 publication Critical patent/FR2963790B1/fr
Priority to IL224632A priority patent/IL224632A/en
Priority to HK13107421.9A priority patent/HK1180298A1/xx
Priority to CY20151100233T priority patent/CY1116088T1/el
Priority to HRP20150265AT priority patent/HRP20150265T1/hr
Priority to US14/748,538 priority patent/US20150291507A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1056560A 2010-08-11 2010-08-11 Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires Active FR2963790B1 (fr)

Priority Applications (30)

Application Number Priority Date Filing Date Title
FR1056560A FR2963790B1 (fr) 2010-08-11 2010-08-11 Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
TW100127261A TWI555528B (zh) 2010-08-11 2011-08-01 泛醇基二十二碳六烯酸酯及其於治療與預防心血管疾病的用途
ARP110102874A AR082594A1 (es) 2010-08-11 2011-08-08 Docosahexanoato de pantenilo y su uso para el tratamiento y prevencion de enfermedades cardiovasculares
MYPI2013000417A MY166065A (en) 2010-08-11 2011-08-11 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
AU2011288410A AU2011288410B2 (en) 2010-08-11 2011-08-11 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
DK11743536.2T DK2603486T3 (en) 2010-08-11 2011-08-11 Panthenyldocosahexaenoate and its use in the treatment and prevention of cardiovascular diseases
ES11743536.2T ES2531437T3 (es) 2010-08-11 2011-08-11 Docosahexaenoato de pantenilo y su utilización para el tratamiento y la prevención de las enfermedades cardiovasculares
US13/816,048 US20130137768A1 (en) 2010-08-11 2011-08-11 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
RS20150175A RS53896B1 (en) 2010-08-11 2011-08-11 PANTENYL DOCOSAHEXAENOATE AND ITS USE FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
HUE11743536A HUE024560T2 (hu) 2010-08-11 2011-08-11 Pantenil-dokozahexanoát, valamint ennek alkalmazása szív-érrendszeri betegségek kezelésére és megelõzésére
RU2013110131/04A RU2593203C2 (ru) 2010-08-11 2011-08-11 Пантенола докозагексаеноат и его применение для лечения и предупреждения сердечно-сосудистых заболеваний
KR1020137004509A KR20140031830A (ko) 2010-08-11 2011-08-11 판테닐 도코사헥사엔오에이트 및 이의 심혈관질환 치료 및 예방용도
JP2013523623A JP5960695B2 (ja) 2010-08-11 2011-08-11 パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用
CA2806154A CA2806154A1 (fr) 2010-08-11 2011-08-11 Docosahexanoate de panthenyle et son utilisation pour traiter et prevenir les maladies cardiovasculaires
PT117435362T PT2603486E (pt) 2010-08-11 2011-08-11 Docosa-hexaenoato de pantenilo e sua utilização para o tratamento e prevenção de doenças cardiovasculares
PCT/EP2011/063854 WO2012020094A1 (fr) 2010-08-11 2011-08-11 Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires
BR112013003149A BR112013003149A2 (pt) 2010-08-11 2011-08-11 docosa-hexaeneoato de pantenila e seu uso para o tratamento e prevenção de doenças cardiovasculares
CN201180036873.2A CN103025707B (zh) 2010-08-11 2011-08-11 泛醇基二十二碳六烯酸酯及其治疗和预防心血管疾病的用途
EP11743536.2A EP2603486B1 (fr) 2010-08-11 2011-08-11 Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires
PL11743536T PL2603486T3 (pl) 2010-08-11 2011-08-11 Dokozaheksaenian pantenylu oraz jego zastosowanie w leczeniu i zapobieganiu chorobom układu sercowo-naczyniowego
MA35677A MA34480B1 (fr) 2010-08-11 2011-08-11 Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires
MX2013001506A MX2013001506A (es) 2010-08-11 2011-08-11 Docosahexanoato de pantenilo y su uso para el tratamiento y prevencion de enfermedades cardiovasculares.
SI201130418T SI2603486T1 (sl) 2010-08-11 2011-08-11 Pantenil dokozaheksaeneonat in njegova uporaba za zdravljenje in preprečevanje kardiovaskularnih bolezni
NZ607836A NZ607836A (en) 2010-08-11 2011-08-11 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
UAA201303028A UA109551C2 (uk) 2010-08-11 2011-11-08 Пантенолу докозагексаєноат і його застосування для лікування і попередження серцево-судинних захворювань
IL224632A IL224632A (en) 2010-08-11 2013-02-07 Fentanyl docushexanavate and its use in the treatment and prevention of cardiovascular disease
HK13107421.9A HK1180298A1 (en) 2010-08-11 2013-06-25 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
CY20151100233T CY1116088T1 (el) 2010-08-11 2015-03-06 Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων
HRP20150265AT HRP20150265T1 (hr) 2010-08-11 2015-03-10 Pantenil-dokosaheksanoat i njegova upotreba za lijeäśenje i sprjeäśavanje kardiovaskularnih bolesti
US14/748,538 US20150291507A1 (en) 2010-08-11 2015-06-24 Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056560A FR2963790B1 (fr) 2010-08-11 2010-08-11 Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Publications (2)

Publication Number Publication Date
FR2963790A1 FR2963790A1 (fr) 2012-02-17
FR2963790B1 true FR2963790B1 (fr) 2012-09-28

Family

ID=43754935

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1056560A Active FR2963790B1 (fr) 2010-08-11 2010-08-11 Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Country Status (29)

Country Link
US (2) US20130137768A1 (fr)
EP (1) EP2603486B1 (fr)
JP (1) JP5960695B2 (fr)
KR (1) KR20140031830A (fr)
CN (1) CN103025707B (fr)
AR (1) AR082594A1 (fr)
AU (1) AU2011288410B2 (fr)
BR (1) BR112013003149A2 (fr)
CA (1) CA2806154A1 (fr)
CY (1) CY1116088T1 (fr)
DK (1) DK2603486T3 (fr)
ES (1) ES2531437T3 (fr)
FR (1) FR2963790B1 (fr)
HK (1) HK1180298A1 (fr)
HR (1) HRP20150265T1 (fr)
HU (1) HUE024560T2 (fr)
IL (1) IL224632A (fr)
MA (1) MA34480B1 (fr)
MX (1) MX2013001506A (fr)
MY (1) MY166065A (fr)
NZ (1) NZ607836A (fr)
PL (1) PL2603486T3 (fr)
PT (1) PT2603486E (fr)
RS (1) RS53896B1 (fr)
RU (1) RU2593203C2 (fr)
SI (1) SI2603486T1 (fr)
TW (1) TWI555528B (fr)
UA (1) UA109551C2 (fr)
WO (1) WO2012020094A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011014386A1 (de) * 2011-03-11 2012-09-13 Hemoteq Ag Endoprothese mit einer Wirkstoffbeschichtung
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
JP6574773B2 (ja) 2014-07-30 2019-09-11 株式会社アエタスファルマ １，４−ベンゾチアゼピン−１−オキシド誘導体の光学異性体、及びそれを用いた医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE496795A (fr)
NL133049C (fr) * 1966-02-24
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale

Also Published As

Publication number Publication date
PT2603486E (pt) 2015-02-18
IL224632A (en) 2016-12-29
CA2806154A1 (fr) 2012-02-16
US20150291507A1 (en) 2015-10-15
TWI555528B (zh) 2016-11-01
RU2013110131A (ru) 2014-09-20
PL2603486T3 (pl) 2015-05-29
AU2011288410B2 (en) 2014-05-22
MA34480B1 (fr) 2013-08-01
HUE024560T2 (hu) 2016-02-29
JP2013538197A (ja) 2013-10-10
AU2011288410A1 (en) 2013-03-21
US20130137768A1 (en) 2013-05-30
NZ607836A (en) 2014-12-24
CN103025707B (zh) 2015-04-29
WO2012020094A1 (fr) 2012-02-16
KR20140031830A (ko) 2014-03-13
UA109551C2 (uk) 2015-09-10
DK2603486T3 (en) 2015-03-02
FR2963790A1 (fr) 2012-02-17
AR082594A1 (es) 2012-12-19
CY1116088T1 (el) 2017-02-08
CN103025707A (zh) 2013-04-03
HK1180298A1 (en) 2013-10-18
RU2593203C2 (ru) 2016-08-10
HRP20150265T1 (hr) 2015-04-10
JP5960695B2 (ja) 2016-08-02
BR112013003149A2 (pt) 2017-03-28
TW201208672A (en) 2012-03-01
MY166065A (en) 2018-05-23
SI2603486T1 (sl) 2015-04-30
ES2531437T3 (es) 2015-03-16
RS53896B1 (en) 2015-08-31
EP2603486A1 (fr) 2013-06-19
EP2603486B1 (fr) 2014-12-17
MX2013001506A (es) 2013-02-27

Similar Documents

Publication Publication Date Title
FR23C1010I2 (fr) Anticorps bispecifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires
GB2478595B (en) Phytocannabinoids in the treatment of glioma
HK1213192A1 (zh) 用於在人類受試者中治療眼部疾病的方法和裝置
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
EP2799539A4 (fr) Arginase humaine et arginase humaine pégylée à point fixe, et leur utilisation
FR2932183B1 (fr) Nouveau polyampholyte, et son utilisation dans le traitement des formations rocheuses
EP2841064A4 (fr) Utilisation de n-acétylcystéine amide dans le traitement de maladies et de lésions
BR112014031086A2 (pt) tratamento e prevenção de doenças cardiovasculares e trombose
HK1164369A1 (en) Preparation of microvesicle-sirna composition and use of the same in aids treatment
FR2950531B1 (fr) Procedes de traitement cosmetique et de deformation permanente des cheveux, utilisation et composition
BR112013014915A2 (pt) composição curativa e métodos de tratamento
IL233875A (en) Preparation and use for the treatment of anal fissures
PT2575973T (pt) Composições anti-inflamatória
FR2944969B1 (fr) Utilisation de n2o gazeux dans le traitement des douleurs chroniques
IL238411A0 (en) Compositions of medicinal plants for the prevention and treatment of tnf-α related diseases
FR2963790B1 (fr) Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
FR2954909B1 (fr) Procedes de traitement cosmetique et kit
FR2954700B1 (fr) Utilisation de polysaccharides dans le traitement du stress et de l'anxiete
FR2962335B1 (fr) Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
FR2930156B1 (fr) Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
GB2483313B (en) Use of probiotic strain GM-080 in treating cardiac inflammation and apoptosis
FR2952823B1 (fr) Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
FR3001391B1 (fr) Utilisation de cellules vegetales d'iridacee elicitees dans le traitement des peaux sensibles
FR2982488B1 (fr) Urotensine ii pour son utilisation dans le traitement et/ou la prevention de pathologies impliquant la motilite gastrique
FR2980360B1 (fr) Utilisation cosmetique de l'hesperidine ou de l'un de ses derives dans la prevention et/ou le traitement des odeurs corporelles.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8